3 completed, 2 active not recruiting, 1 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Active not recruiting 2, Terminated 1 |
Follow asciminib: new trials by email Literature Review of asciminib trials Research Report on asciminib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) Asciminib, Nilotinib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 568 | 2022-11-21 | 2026-08-26 |
| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 199 | 2021-10-13 | 2026-03-18 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation ABL001 - Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Completed | Novartis Pharmaceuticals | 56 | 2021-05-25 | 2025-10-16 |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Asciminib, Bosutinib - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 233 | 2017-10-26 | 2026-08-18 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Philadelphia Chromosome (2) · Leukemia (1) · Leukemia, Myeloid, Chronic-Phase (1) · Myeloproliferative Disorders (1)
Novartis Pharmaceuticals (5) · Sarit Assouline (1)
Canada (5) · France (4) · Germany (4) · Italy (4) · South Korea (4) · United Kingdom (4) · United States (4) · Argentina (3) · Bulgaria (3) · Czechia (3) · Hungary (3) · Malaysia (3) · Netherlands (3) · Singapore (3) · Spain (3)
Sarit E Assouline, MD, MSc (1)
PMID 34407542, PMID 35764773, PMID 36168187, PMID 36524980, PMID 37431294, PMID 38820078, PMID 40334072, PMID 41397287, PMID 42339511
2016 (1), 2023 (1)